The most important financial indicators for the company Imolapharm Srl - Unique Identification Number 17260536:
sales in 2023 was
397.254
euro, registering a net profit of
38.095
euro and having an average number of
4
employees.
Firma isi desfasoara activitatea in domeniul Comert cu amanuntul al produselor farmaceutice, in magazine specializate having the NACE code 4773.
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded.
In the last year of activity, the sales decreased by -0.1%, from 398.904 euro in the year 2022, to 397.254 euro in 2023.
The Net Profit increased by 5.985 euro, from 32.208 euro in 2022, to 38.095 in the last year.
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
147.105 euro in 2023 which includes Inventories of
67.493 euro, Receivables of
73.928 euro and cash availability of
5.684 euro.
The company's Equity was valued at
42.787 euro, while total Liabilities amounted to
116.459 euro.
Equity increased by 10.627 euro, from 32.257 euro in 2022, to 42.787 in 2023.
Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Imolapharm Srl